Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.638 USD | +1.97% | -1.37% | -5.17% |
05-17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
04-02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.17% | 18.34M | |
+38.03% | 723B | |
+34.22% | 595B | |
-2.78% | 369B | |
+20.51% | 332B | |
+2.60% | 282B | |
+17.04% | 244B | |
+9.51% | 208B | |
-4.70% | 205B | |
+0.47% | 168B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Transcript : Kala Pharmaceuticals, Inc., Q1 2020 Earnings Call, May 07, 2020